ALXO

MKT CAP:$89M

ALX Oncology Holdings Inc.

Market Cap

$89M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$1.59+$0.44 (+38.26%)

Apr 23, 2026

Company Details

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used ...

CEO

Jason W. Lettmann

IPO Date

Jul 17, 2020

Website

www.alxoncology.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$102M

EPS (Diluted)

-$1.90

Free Cash Flow

-$84M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q1 2026

May 14, 2026

PENDING

FY 2025

Mar 9, 2026

$0EPS -$1.90

Q4 2025

Mar 9, 2026

$0EPS -$0.42

Q3 2025

Nov 7, 2025

$0EPS -$0.41

Q2 2025

Aug 12, 2025

$0EPS -$0.49

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$0	$0	-$25M
Q2 22	$0	$0	-$34M
Q3 22	$0	$0	-$37M
Q4 22	$0	-$413.0K	-$32M
Q1 23	$0	$0	-$32M
Q2 23	$0	$0	-$37M
Q3 23	$0	$0	-$53M
Q4 23	$0	$0	-$48M
Q1 24	$0	-$214.0K	-$38M
Q2 24	$0	-$220.0K	-$42M
Q3 24	$0	$0	-$33M
Q4 24	$0	$0	-$31M
Q1 25	$0	$0	-$32M
Q2 25	$0	$0	-$27M
Q3 25	$0	$0	-$23M
Q4 25	$0	$0	-$23M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$21M	-$21M
Q2 22	-$17M	-$17M
Q3 22	-$31M	-$31M
Q4 22	-$21M	-$21M
Q1 23	-$28M	-$29M
Q2 23	-$32M	-$33M
Q3 23	-$31M	-$30M
Q4 23	-$40M	-$40M
Q1 24	-$38M	-$38M
Q2 24	-$27M	-$27M
Q3 24	-$25M	-$26M
Q4 24	-$32M	-$32M
Q1 25	-$25M	-$25M
Q2 25	-$23M	-$23M
Q3 25	-$17M	-$17M
Q4 25	-$19M	-$19M

Capital Expenditures

Quarter	CapEx
Q1 22	$589.0K
Q2 22	$257.0K
Q3 22	$192.0K
Q4 22	$389.0K
Q1 23	$690.0K
Q2 23	$2M
Q3 23	$1M
Q4 23	$148.0K
Q1 24	$148.0K
Q2 24	$90.0K
Q3 24	$149.0K
Q4 24	$60.0K
Q1 25	$60.0K
Q2 25	$47.0K
Q3 25	$56.0K
Q4 25	$49.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	—	+74.2%
Q2 22	—	+107.3%
Q3 22	—	+49.3%
Q4 22	—	+13.2%
Q1 23	—	+30.1%
Q2 23	—	+8.8%
Q3 23	—	+45.2%
Q4 23	—	+49.1%
Q1 24	—	+17.3%
Q2 24	—	+12.9%
Q3 24	—	-38.9%
Q4 24	—	-36.3%
Q1 25	—	-15.7%
Q2 25	—	-35.8%
Q3 25	—	-30.8%
Q4 25	—	-24.8%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$0	—
Q2 22	$0	—
Q3 22	$0	—
Q4 22	$0	—
Q1 23	$6M	—
Q2 23	$0	—
Q3 23	$7M	—
Q4 23	$7M	—
Q1 24	$7M	—
Q2 24	$7M	—
Q3 24	$7M	—
Q4 24	$6M	—
Q1 25	$5M	—
Q2 25	$2M	—
Q3 25	$3M	—
Q4 25	$3M	—

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 22	$17M	$8M	—
Q2 22	$27M	$7M	—
Q3 22	$29M	$7M	—
Q4 22	$25M	—	$7M
Q1 23	$25M	$7M	—
Q2 23	$29M	$7M	—
Q3 23	$46M	$8M	—
Q4 23	$42M	$6M	—
Q1 24	$32M	$6M	—
Q2 24	$35M	$7M	—
Q3 24	$26M	$6M	—
Q4 24	$24M	$7M	—
Q1 25	$24M	$8M	—
Q2 25	$18M	$5M	—
Q3 25	$17M	$5M	—
Q4 25	$18M	—	$5M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$159M	$158M	$317M
Q2 22	$66M	$247M	$313M
Q3 22	$49M	$236M	$285M
Q4 22	$49M	$217M	$266M
Q1 23	$63M	$165M	$228M
Q2 23	$38M	$175M	$213M
Q3 23	$20M	$170M	$190M
Q4 23	$22M	$160M	$183M
Q1 24	$14M	$143M	$157M
Q2 24	$16M	$141M	$157M
Q3 24	$16M	$132M	$149M
Q4 24	$18M	$110M	$128M
Q1 25	$21M	$77M	$98M
Q2 25	$19M	$60M	$79M
Q3 25	$23M	$37M	$61M
Q4 25	$16M	$28M	$45M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	41M	+0.2%	+1.4%
Q2 22	41M	+0.2%	+1.1%
Q3 22	41M	+0.1%	+0.9%
Q4 22	41M	+0.0%	+0.6%
Q1 23	41M	+0.3%	+0.6%
Q2 23	41M	+0.0%	+0.5%
Q3 23	41M	+0.7%	+1.0%
Q4 23	49M	+19.1%	+20.2%
Q1 24	50M	+2.3%	+22.7%
Q2 24	52M	+3.4%	+26.8%
Q3 24	53M	+1.7%	+28.1%
Q4 24	53M	+0.2%	+7.8%
Q1 25	53M	+1.1%	+6.5%
Q2 25	53M	+0.2%	+3.1%
Q3 25	54M	+0.2%	+1.7%
Q4 25	54M	+1.3%	+2.8%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$0	43
Q2 22	$0	43
Q3 22	$0	43
Q4 22	$0	58
Q1 23	$0	58
Q2 23	$0	58
Q3 23	$0	58
Q4 23	$0	72
Q1 24	$0	72
Q2 24	$0	72
Q3 24	$0	72
Q4 24	$0	80
Q1 25	$0	80
Q2 25	$0	80
Q3 25	$0	80
Q4 25	$0	200K

Revenue / Employee